Condition (MeSH)
Osteitis
ClinicalTrials.gov lists 9 trials for Osteitis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
9 of the 9 trials are tagged with Osteitis itself; the rest are tagged with a narrower condition beneath it.
When did Osteitis trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 2 |
| 2021 | 1 |
| 2019 | 1 |
| 2015 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 9 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteitis trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 3 |
| Observational | 5 |
How many Osteitis trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 4 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Osteitis? (44)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Performance of an MRI scoring system for inflammation of joints and entheses in peripheral SpA: post-hoc analysis of the CRESPA trial. | Rheumatology (Oxford, England) | 2023 | Yes |
| Effect of initiating biologics compared to intensifying conventional DMARDs on clinical and MRI outcomes in established rheumatoid arthritis patients in clinical remission: Secondary analyses of the IMAGINE-RA trial. | Scandinavian journal of rheumatology | 2022 | Yes |
| Peripheral enthesitis assessed by whole-body MRI in axial spondyloarthritis: Distribution and diagnostic value. | Frontiers in immunology | 2022 | Yes |
| Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis. | Annals of the rheumatic diseases | 2017 | Yes |
| Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis. | Annals of the rheumatic diseases | 2017 | Yes |
Showing 5 of 44 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.